NDANASALSPRAY, METEREDPriority Review
Approved
Feb 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
DDAVP (NEEDS NO REFRIGERATION) (desmopressin acetate) by Ferring Pharmaceuticals is acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (v2) receptors. Approved for nocturia. First approved in 1978.
Drug data last refreshed 20h ago
Mechanism of Action
acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine…
Indications (1)
Clinical Trials (1)
Desmopressin Acetate 0.2 mg Tablets, Fasting
Started Jul 2003
48 enrolled
Healthy
Company
Worked on DDAVP (NEEDS NO REFRIGERATION) at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.